Sibutramine and CV events

In this preliminary analysis of data released from a large clinical trial of sibutramine (Meridia), participants randomized to sibutramine had higher rates of cardiovascular events (MI, CVA, cardiac arrest, or death) than those randomized to placebo (11.4% vs 10%). The FDA recommends patients with a history of CAD, CHF, CVA, or arrythmias not be prescribed sibutramine (FDA site)

Danielle Scheurer

Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.

Leave a Comment